12hon MSN
New organ-on-a-chip platform allows the testing of cancer vaccine efficacy in aging populations
Dr. Vadim Jucaud's lab at the Terasaki Institute has introduced a new organ-on-a-chip platform that recapitulates ...
Review of recent advances in biomimetic drug delivery for rheumatoid arthritis, highlighting targeted nanomedicine strategies ...
The MAD portion of this clinical trial is powered to demonstrate human proof-of-concept for the use of ABS-201 to treat androgenetic alopecia by stimulating significant hair regrowth. The company ...
ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that the company has been awarded a $10.8 million grant from the Cancer ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the completion of its Phase IIa clinical study for 9MW1911, a self-developed ...
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate ...
EO2401 in vivo immune therapy + nivolumab +/- bevacizumab shows survival benefit in first recurrent glioblastomaData presented at 2025 SNO ...
Investor's Business Daily on MSN
Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10
Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed ...
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...
News-Medical.Net on MSN
Organ-on-a-chip system reveals how aging weakens vaccine-driven anti-cancer immunity
Dr. Vadim Jucaud's lab at the Terasaki Institute has introduced a new organ-on-a-chip platform that recapitulates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback